Literature DB >> 2661744

Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage.

M Zuccarello1, J T Marsch, G Schmitt, J Woodward, D K Anderson.   

Abstract

The purpose of this study was to use a new 21-aminosteroid (U-74006F) with in vitro antioxidant and antilipolytic properties as a pharmacological probe to assess the role of lipid hydrolysis and peroxidation in a rabbit model of subarachnoid hemorrhage (SAH)-induced vasospasm. Cerebral angiograms were performed on 15 rabbits. Eighteen hours later, 1 cc/kg of autologous blood was infused into the cisterna magna of all 15 animals. Six rabbits received no treatment, six received U-74006F starting 30 minutes after SAH, and three rabbits received the vehicle for U-74006F starting 30 minutes after SAH. At 72 hours post-SAH, a second angiogram was obtained. Digital subtraction angiographic techniques were used to measure the diameter of and contrast material flow through the basilar artery. At 72 hours post-SAH, vasospasm was evident in all untreated and vehicle-treated rabbits. The diameter of and the flow through the basilar artery were significantly reduced 42.3% +/- 6.6% and 46.8% +/- 5.8%, respectively, below pre-SAH levels (means +/- standard error of the means). Treatment with U-74006F eliminated the SAH-induced vasospasm; in treated animals, both the flow through and the diameter of the basilar arteries were at pre-SAH levels. These findings indicate that: 1) membrane lipid changes (that is, hydrolysis with eicosanoid production and/or peroxidation) contribute to the chronic vasospasm resulting from SAH, and 2) U-74006F prevents the SAH-induced chronic vasospasm in this model by limiting these pathological membrane events.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661744     DOI: 10.3171/jns.1989.71.1.0098

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

Review 1.  Antioxidant strategies in neurocritical care.

Authors:  Khalid A Hanafy; Magdy H Selim
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Pharmacologic reduction of angiographic vasospasm in experimental subarachnoid hemorrhage: systematic review and meta-analysis.

Authors:  Tommaso Zoerle; Don C Ilodigwe; Hoyee Wan; Katarina Lakovic; Mohammed Sabri; Jinglu Ai; R Loch Macdonald
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-25       Impact factor: 6.200

Review 3.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

Review 4.  The single and double blood injection rabbit subarachnoid hemorrhage model.

Authors:  Yuichiro Kikkawa; Ryota Kurogi; Tomio Sasaki
Journal:  Transl Stroke Res       Date:  2014-11-08       Impact factor: 6.829

5.  PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF.

Authors:  Gail J Pyne-Geithman; Sunil G Nair; Danielle N Caudell; Joseph F Clark
Journal:  Front Biosci       Date:  2008-01-01

6.  Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm.

Authors:  R E Ayer; J H Zhang
Journal:  Acta Neurochir Suppl       Date:  2008

7.  The effect of Nicorandil on chronic cerebral vasospasm.

Authors:  T Matsui; T Nagafuji; K Tsutsumi; H Uchida; T Miyauchi; T Asano
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Effect of intraventricular haemorrhage and rebleeding following subarachnoid haemorrhage on CSF eicosanoids.

Authors:  J D Pickard; V Walker; L Brandt; S Zygmunt; J Smythe
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 9.  Lazaroids. CNS pharmacology and current research.

Authors:  W M Clark; J S Hazel; B M Coull
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.